XKH004 / Kanova Biopharma, Livzon Pharma - LARVOL DELTA

Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review. (PubMed, Am J Clin Dermatol) - "Key agents under investigation include netakimab, vunakizumab, xeligekimab, gumokimab, HB0017, CJM 112, JS005, 608, LZM012, ZL-1102, izokibep, sonelokimab, DC-806, DC-853, and LEO 153339. Both preclinical and clinical trial data for each agent are summarized, with an emphasis on their efficacy, adverse effects, immunogenicity, and future outlooks."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study (ACR Convergence 2024) - "Background/Purpose: XKH004, the first recombinant anti-human IL-17A/F humanized monoclonal antibody in China (also known as XKH004), shares the same therapeutic target as Bimekizumab from UCB pharma, the first biologic targeting IL-17 A/F (XKH004 is the second one worldwide). In patients with active AS, various dosages of XKH004 effectively improved disease activity. The safety and tolerability profile were favorable, and no immunogenicity risk was identified for up to 24 weeks."

Clinical • P2 data • Ankylosing Spondylitis • Back Pain • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Pain • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Psoriasis: A Study to Evaluate the Efficacy and Safety of LZM012 (clinicaltrials.gov) - P3 | N=918 | Recruiting | Sponsor: Livzon Pharmaceutical Group Inc.

New P3 trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis